Pieris links with Strides' arm in second Indian tie up for Anticalin therapeutics
This article was originally published in Scrip
Executive Summary
German biotech firm Pieris and Stelis Biopharma, a subsidiary of India's Strides Arcolab, have initiated a long-term alliance to develop and commercialize certain novel Anticalin-based protein therapeutics mainly focused on the ophthalmology segment.